46
Views
25
CrossRef citations to date
0
Altmetric
Original Article

The Inhibitory Effects of Pure Flavonoids on in Vitro Protein Glycosylation

, , &
Pages 47-55 | Received 12 Mar 2001, Accepted 11 Jul 2001, Published online: 20 Aug 2009
 

Abstract

Non-enzymatic glycosylation of proteins is the major cause of diabetic complications, such as cardiovascular disorders, retino-pathy, nephropathy and neuropathy. It seems that protein glycosylation can be inhibited effectively by antioxidants. Several flavonoids, such as rutin, kaempferol, quercetin, apigenin, naringin, morin and biochanin A were selected to determine their antioxidant effects on in vitro insulin, hemoglobin and albumin glycosylation. The optimal glucose concentration and incubation time were obtained for each protein. Then, the inhibition percentage of protein glycosylation was measured in the presence of three different concentrations (0.5,5,10 ng/ml) of each flavonoids by a colorimetric method. The results demonstrated that biochanin A, the best inhibitor of insulin and hemoglobin glycosylation, inhibits their glycosylation 100%and 60%, respectively. Glycosylation of albumin was inhibited 100%by both biochanin A and apigenin. Therefore, it seems probable that plants containing flavonoids may have preventive effects in diabetic complications.

Additional information

Notes on contributors

Roshanak Vakili

F. U. Alakbarov is Head Scientific Officer, expert in the Oriental and Folk Medicine, Institute of Manuscripts of the Azerbaijan Academy of Sciences, 8 Istiglaliyat str., Baku, 370001, Azerbaijan.

At the time of writing Liya Davydov was PharmD candidate, College of Pharmacy and Allied Health Professions, St. John's University. Currently, she is Pharmacy Practice Resident, Mount Sinai Medical Center, New York, NY.

Ila Mehra Harris is Assistant Professor, Department of Pharmaceutical Care & Health Systems, College of Pharmacy, and Clinical Assistant Professor, Department of Family Practice & Community Health, Medical School, University of Minnesota, Minneapolis, MN.

Colin J. Briggs is Professor of Pharmacy, Faculty of Pharmacy, University of Manitoba. Recently he completed a secondment to Health Canada, as Senior Science Advisor in the Therapeutics Products Programme with special responsibility for complementary medicines.

Gemma Briggs is Research Assistant, IMPACT, The Injury Prevention Centre of Children's Hospital, 501G-715 John Buhler Research Centre, Winnipeg, MB, Canada.

Mary Chavezis Professor of Pharmacy Practice, Director of Complementary Medicine Education and Research, The Center for the Advancement of Pharmacy Practice, Midwestern University, College of Pharmacy Glendale, Glendale, AZ 85308.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.